[Form 4] VIEMED HEALTHCARE, INC. Insider Trading Activity

Rhea-AI Filing Summary

Viemed Healthcare General Counsel Jeremy Trahan reported multiple equity-related transactions on January 21, 2026. He exercised and vested 14,648 Restricted Stock Units, each converting into one common share, bringing his directly held common shares at one point to 43,440.

To cover taxes from the RSU vesting, the company withheld 4,783 common shares at a per-share value of $7.49, leaving Trahan with 38,657 common shares after that step. He also had 3,662 cash-settled phantom share units vest under the Phantom Share Unit Plan, economically equivalent to common shares, with settlement reported as both acquisition and disposition of the related common shares.

Following these transactions, Trahan held 29,296 Restricted Stock Units and 7,324 phantom share units, both scheduled to vest in equal annual installments through January 21, 2028, aligning a portion of his compensation with Viemed Healthcare’s share performance over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trahan Jeremy

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/21/2026		M		14,648	A	(1)	43,440	D
Common Shares	01/21/2026		F		4,783(2)	D	$7.49(3)	38,657	D
Common Shares	01/21/2026		M		3,662	A	(4)	42,319	D
Common Shares	01/21/2026		D		3,662	D	$7.49(3)	38,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/21/2026		M			14,648	(5)	01/21/2028	Common Shares	14,648	$0	29,296	D
Phantom Share Units	(4)	01/21/2026		M			3,662	(6)	01/21/2028	Common Shares	3,662	(4)	7,324	D

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.

2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.

3. Per share value is based on the market closing price of the common shares for January 21, 2026.

4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.

5. Restricted Stock Units (RSUs) granted to reporting person on January 21, 2025, which vest in three equal annual installments beginning on the first anniversary of the grant date.

6. Represents an award granted on January 21, 2025 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Viemed Healthcare (VMD) General Counsel Jeremy Trahan report on this Form 4?

General Counsel Jeremy Trahan reported the vesting and exercise of Restricted Stock Units and phantom share units on January 21, 2026, along with related acquisitions and dispositions of Viemed Healthcare common shares.

How many Viemed Healthcare RSUs vested for Jeremy Trahan on January 21, 2026?

14,648 Restricted Stock Units vested and were exercised into an equal number of Viemed Healthcare common shares, as each RSU represents the right to receive one common share.

Why were 4,783 Viemed Healthcare common shares deducted from Jeremy Trahan’s holdings?

The 4,783 common shares were withheld by the issuer to satisfy Trahan’s tax obligations arising from the RSU vesting, using a per-share value of $7.49, the market closing price on January 21, 2026.

What are Viemed Healthcare phantom share units reported by Jeremy Trahan?

The phantom share units are cash-settled awards under Viemed Healthcare’s Phantom Share Unit Plan. Each phantom share is the economic equivalent of one common share, and on January 21, 2026 Trahan had 3,662 units vest with settlement reported as both acquisition and disposition of equivalent common shares for cash.

How many Viemed Healthcare common shares did Jeremy Trahan own after these Form 4 transactions?

After the reported transactions on January 21, 2026, Trahan’s directly owned Viemed Healthcare common shares were shown as 38,657 in the filing.

What ongoing equity awards does Jeremy Trahan retain with Viemed Healthcare (VMD)?

Following the transactions, Trahan held 29,296 Restricted Stock Units and 7,324 phantom share units, which are scheduled to vest in three equal annual installments beginning on January 21, 2026 and ending on January 21, 2028.